Media Articles Related to Exforge (Amlodipine / Valsartan)
Masked Hypertension Linked to Cognitive Decline
Source: theheart.org | Medscape Cardiology Headlines [2015.05.22]
Ambulatory blood-pressure measurements may reveal "the hidden risk" of diminished cognitive function in older patients, say researchers. In addition, this risk may be increased twofold, they report.
Heartwire from Medscape
New data show need for improved monitoring for pulmonary hypertension following pulmonary embolism
Source: Respiratory / Asthma News From Medical News Today [2015.05.20]
Results from a retrospective cohort study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among...
Managing Hypertension: Technology Challenges Old Habits
Source: MedPage Today Cardiovascular [2015.05.20]
(MedPage Today) -- More accurate automated readings should replace the standard of care in the U.S., says one advocate
American Society of Hypertension (ASH) 2015 Annual Scientific Meeting
Source: theheart.org | Medscape Cardiology Headlines [2015.05.18]
Read clinically focused news coverage of key developments from ASH 2015.
Odd genetic syndrome suggests increased blood vessel resistance could cause hypertension
Source: Hypertension News From Medical News Today [2015.05.13]
The culmination of two decades of research, a new study reveals the genetic causes of a curious, rare syndrome that manifests as hypertension (high blood pressure) accompanied by short fingers...
Published Studies Related to Exforge (Amlodipine / Valsartan)
Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. [2011.09]
Achieving target blood pressure (BP) is influenced by baseline BP. Post hoc analyses of a placebo-controlled trial of amlodipine/valsartan versus monotherapies were conducted to characterize BP control by baseline BP...
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. [2011.07]
Combination therapy may reduce racial/ethnic differences in response to antihypertensives. In this post-hoc analysis, we evaluated treatment response by race/ethnicity among hypertensive adults enrolled in a 12-week, double-blind study in which patients previously uncontrolled (mean sitting systolic blood pressure [MSSBP] >/=150 and <200 mm Hg) on angiotensin receptor blocker (ARB) monotherapy (other than valsartan) for 28 days or more (n = 728) were randomized to amlodipine/valsartan 10/320 mg (intensive) or 5/160 mg (moderate)...
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. [2011.06]
The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study... All treatments were safe and well tolerated.
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. [2011.04]
OBJECTIVES: Ambulatory blood pressure monitoring (ABPM) has greater predictive value than office blood pressure (BP) with respect to hypertension-related target-organ damage and morbidity. ABPM in a subset of 80 patients from the Exforge Target Achievement trial (N=728) was used to compare the efficacy of intensive-treatment and moderate-treatment regimens of amlodipine/valsartan, and to determine whether treatment differences could be better assessed with ABPM than with office or home BP. Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures... CONCLUSION: In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial.
Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. [2011.04]
OBJECTIVES: This study compared the effects of morning and evening dosing of amlodipine/valsartan combination on 24-h blood pressure (BP) in patients uncontrolled by amlodipine (5 mg)... CONCLUSION: These results indicate that, in patients with BP uncontrolled by amlodipine (5 mg), morning and evening treatment with amlodipine/valsartan combination have similar effects on circadian BP, especially when 24-h mean values are considered.
Clinical Trials Related to Exforge (Amlodipine / Valsartan)
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily
administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in
patients with essential hypertension.
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension [Completed]
The purpose of this study is to evaluate the safety and efficacy of fixed combination of
valsartan (40 mg and 80 mg) and amlodipine (2. 5 mg and 5 mg), valsartan and amlodipine alone,
and placebo in reducing blood pressure. The study will investigate the dose response
relationship for the combinations, monotherapies and placebo.
Effectiveness of EXforge® and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients [Recruiting]
This study is to demonstrate that valsartan/amlodipine 80/5 mg has superior efficacy
compared with nifedipine 30mg alone in reducing the mean sitting diastolic blood pressure
(MSDBP) and mean sitting systolic blood pressure (MSSBP) from baseline in patients with mild
to moderate hypertension not adequately controlled with monotherapy.
A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects [Not yet recruiting]
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension. [Completed]
This trial will compare valsartan and amlodipine combination therapies to both valsartan and
amlodipine, and placebo for the treatment of hypertension.
Reports of Suspected Exforge (Amlodipine / Valsartan) Side Effects
Blood Pressure Increased (85),
Oedema Peripheral (57),
Cerebrovascular Accident (57),
Diabetes Mellitus (44),
Dyspnoea (33), more >>